Shanghai HeartCare Medical Technology Corporation Limited (HeartCare) has granted 30,000 H-share awards to a single employee on 21 September 2026 under its 2025 H Share Incentive Scheme.

The new grant equals 0.10% of the company’s issued H shares and 0.08% of total share capital (both figures exclude treasury shares). No consideration is payable by the grantee. The closing price of HeartCare’s H shares on the grant date was HK$55.00.

Vesting is divided into:

• One-year tranche: 3,000 shares • Three-year tranche: 27,000 shares

Awards will be assessed across four fiscal years (2026-2029). Vesting dates fall on 30 September of the subsequent year for the first two assessment periods and on 30 September and 31 March for the last two, with a possible extension to 31 March 2031 if performance conditions are not fully met.

Performance hurdles require the recipient to attain at least a “B” rating in annual personal evaluations and for the Group to grow revenue by 47% in 2026, 40% in 2027, and 35% in both 2028 and 2029 versus the prior year. The Board retains claw-back rights in cases of misconduct, reputational harm, or financial misstatements.

Following this award, 2.87 million H shares remain available for future grants, representing 9.37% of outstanding H shares and 7.37% of total issued capital. The grant does not require shareholder approval under Hong Kong Listing Rules, as the recipient is neither a director, chief executive, substantial shareholder, nor related entity participant, and no financial assistance has been provided for the share acquisition.